AlphaLiquid® Platform

Our Solution

Early detection of cancer.

Cell-free DNA (cfDNA) is circulating fragments of DNA that is released from cells into the circulatory system throughout the body.

Tumor cells also release DNA into the blood stream, which is called circulation-tumor DNA(ctDNA).

IMBdx Inc.’s AlphaLiquid® platform offers industry-leading ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection(AlphaLiquid® 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect™),

and multi-cancer early detection (CancerFind™)

What is Liquid Biopsy?

Liquid biopsy uses body fluids such as blood, cerebrospinal fluid, pleural effusion and urine to analyze trace amounts of ctDNA shed by tumor cells. Analysis of ctDNA can yield clinically actionable information to identify druggable targets, monitor therapy response, detect recurrence or screen for early-stage cancer.

Unlike tissue biopsies which involve invasive surgical procedures to obtain tumor tissue, liquid biopsies are based on non-invasive collection of body fluids such as a simple blood draw.

Minimally Invasive Specimen Collection

Reflection of Tumor Heterogeneity

Mutation-based Therapy Matching

Non-invasive blood sample collection and cancer monitoring
Overcomes tumor heterogeneity for effective precision therapy strategy
ctDNA progression precedes radiological progression by a significant lead time, enabling earlier detection